STOP-HCC

Clinical Trial Information

Protocol TS-103 / NCT0155649


An open-label, prospective, multicenter, randomized, Phase III clinical trial evaluating yttrium-90 transarterial radioembolization (TheraSphere®) in the treatment of patients with unresectable hepatocellular carcinoma (HCC).27,28


RANDOMIZE TREATMENT GROUP

TheraSphere® prior to initiation of standard-of-care therapy: sorafenib


CONTROL GROUP

Standard-of-care therapy: sorafenib


OBJECTIVES

To evaluate the efficacy and safety of TheraSphere® in patients with unresectable HCC in whom treatment with sorafenib is planned.


ENDPOINTS

Primary: Overall survival
Secondary: Time to progression, tumor response, time to symptomatic progression, quality of life (FACT-hep), time to untreatable progression, safety

Please visit the  THERASPHERE TRIALS WEBSITE for more details